Taltz and Zepbound Combination | 1-Year Clinical Trial Results

One-Year Results for Combined Psoriatic and Obesity Treatment

Eli Lilly and Company released 52-week clinical data today showing that the combined use of Taltz and Zepbound produces lasting benefits for adults living with psoriatic disease and obesity. The TOGETHER-PsO and TOGETHER-PsA trials followed 545 participants over one year to assess whether treating the two conditions concurrently offers better outcomes than using Taltz alone. Participants in the trials all carried a body mass index of at least 30, or a BMI of 27 with at least one weight-related condition. The results confirm that combining these two medications maintains or increases improvements in disease activity and metabolic health.

At the one-year mark, patients receiving both treatments showed clearer skin and reduced joint inflammation compared to those on monotherapy. In the plaque psoriasis study, 30.6% of patients on the combined regimen achieved both complete skin clearance and at least 10% weight loss. Only 4.4% of the monotherapy group reached that same benchmark. For those with psoriatic arthritis, 39.2% of the combination group achieved a 50% reduction in disease activity alongside the 10% weight loss target. The monotherapy group reported a 1.7% success rate for these specific criteria.

Understanding the Immunometabolic Connection

Psoriasis and psoriatic arthritis frequently overlap with metabolic dysfunction. Roughly 65% of people with psoriatic arthritis also carry excess weight, a factor often linked to reduced effectiveness of standard biological treatments. Before these trials, clinical approaches typically addressed skin or joint issues separately from body weight. These findings suggest that addressing both inflammation and metabolism simultaneously provides a more effective path for long-term health.

Dr. Joseph F. Merola, a dermatologist and rheumatologist, noted that the benefits in joint activity appeared as early as the first month of the study. This timeframe occurred before the participants experienced significant weight loss. The persistence of these improvements through the 52-week point indicates that the combination protocol offers a durable intervention. Skin clearance rates also remained stable, proving that the dual approach does not sacrifice dermatological success to manage metabolic concerns.

Future Implications for Clinical Practice

The safety profile for the combined treatment aligned with existing data for each individual medication. Common adverse events included nausea, diarrhea, constipation, and injection site reactions. The researchers reported that these events were generally mild or moderate. These results provide the first evidence supporting the use of an incretin therapy alongside a biologic for this specific patient population.

Lilly plans to share detailed data from the 52-week follow-up at upcoming medical conferences and in peer-reviewed journals. This study highlights a shift in how medical providers might view chronic disease management. By acknowledging the interplay between systemic inflammation and weight, doctors may adopt more integrated strategies. These trials suggest that tackling both issues at once improves the standard of care for millions of adults currently struggling with the dual burden of psoriatic disease and obesity.